Aldeyra Therapeutics (NASDAQ:ALDX) “Buy” Rating Reiterated Today By Cantor Fitzgerald; The Target Given is $23.0000

May 17, 2018 - By Rusty Cady

Investors sentiment decreased to 1.62 in Q4 2017. Its down 1.51, from 3.13 in 2017Q3. It dived, as 5 investors sold Aldeyra Therapeutics, Inc. shares while 8 reduced holdings. 9 funds opened positions while 12 raised stakes. 9.98 million shares or 45.35% less from 18.26 million shares in 2017Q3 were reported.

Dimensional Fund L P holds 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 50,923 shares. Hikari Power holds 0.09% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 107,858 shares. Renaissance Limited Liability reported 62,100 shares. Comml Bank Of Ny Mellon holds 18,378 shares or 0% of its portfolio. Northern Tru Corporation reported 0% stake. Hightower Lc has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Geode Cap Management Ltd Co reported 102,263 shares. Mangrove Prtn reported 164,384 shares or 0.15% of all its holdings. Acadian Asset Mngmt invested in 5,534 shares or 0% of the stock. Fmr Limited Co has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 1.61 million shares. Peddock Advisors Lc invested in 0% or 752 shares. 1,700 are held by Deutsche Bancorp Ag. The Massachusetts-based Adage Partners Group Lc has invested 0.01% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Vanguard Gp holds 0% or 698,534 shares in its portfolio. Blackrock holds 37,694 shares.

Aldeyra Therapeutics (NASDAQ:ALDX) Rating Reaffirmed

Recently, In a research note revealed to clients on Tuesday morning, Aldeyra Therapeutics (NASDAQ:ALDX) shares have had their “Buy” Rating reiterated by stock analysts at Cantor Fitzgerald, who currently has a $23.0000 target price on company. This target by Cantor Fitzgerald means the possibile upside of 158.43 % from the current price.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics has $2300 highest and $13 lowest target. $18’s average target is 102.25% above currents $8.9 stock price. Aldeyra Therapeutics had 2 analyst reports since January 26, 2018 according to SRatingsIntel. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, March 29.

The stock increased 5.33% or $0.45 during the last trading session, reaching $8.9. About 117,719 shares traded or 25.81% up from the average. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 55.45% since May 17, 2017 and is uptrending. It has outperformed by 43.90% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $175.02 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More notable recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: Seekingalpha.com which released: “2 Small Biotechs To Consider” on April 27, 2018, also Benzinga.com with their article: “22 Stocks Moving In Friday’s Pre-Market Session” published on May 11, 2018, Seekingalpha.com published: “Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018. More interesting news about Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” published on May 15, 2018 as well as Benzinga.com‘s news article titled: “Earnings Scheduled For May 15, 2018” with publication date: May 15, 2018.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.